Sanofi stock up on Pfizer buyout talk

Sanofi-Aventis stock spiked this morning after rumors of a Pfizer buyout sparked a flurry of trading. The oil company Total does own 13 percent of Sanofi, and it has been looking to offload those shares. Pfizer was rumored to have approached Total four years ago, but that was before the Aventis merger boosted Sanofi's market cap to some $121 billion.

The rationale: Pfizer would buy Total's shares and use them as a foot in the door to an eventual buyout. L'Oreal owns another ten percent, and though it has said it's not interested in selling, that doesn't quell takeover talk. Neither Sanofi nor Pfizer would comment.

- read the report from Lab Technologist
- see this Pharmalot item

Related Articles:
Pfizer, Wyeth merger bad idea? Report
Wyeth buyout a good deal for Pfizer? Report
Sanofi underscores pipeline advances, setbacks. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.